Evaluating the efficacy of rimegepant as a preventive treatment for chronic and episodic migraine: a three-month longitudinal retrospective cohort study

1

Rimegepant is an oral CGRP receptor antagonist effective for both acute and preventive migraine treatment, with limited real-world evidence prior to this study.
2

This retrospective cohort study involved 40 adults with chronic or episodic migraine, assessing the impact of rimegepant over three months.
3

Significant improvements were observed in monthly headache days, monthly migraine days, and patient-reported outcomes after three months of rimegepant treatment.
4

Both chronic and episodic migraine patients experienced meaningful reductions in headache frequency and disability, with improvements noted as early as Month 1.
5

These findings support the potential of rimegepant for chronic migraine prevention, although further prospective studies are needed to confirm efficacy.

1